01 Nov Thoeris Gmbh
Thoeris Gmbh are an early stage company developing therapeutic interventions for treating orphan diseases with high unmet medical need. Their lead product is targeted at reducing Hyperammonemia, a condition that may be congenital or associated with other diseases such as Hepatic Encephalopathy.
BioCity invested in Thoeris Gmbh because of the unique approach which we believe will be complimentary to existing solutions targeting a real unmet need. Leveraging the orphan application is a significant strategic factor for a small company.